Symptomatic Clusters Related to Amyloid Positivity in Cognitively Unimpaired Individuals.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Sannemann Lena, Bartels Claudia, Brosseron Frederic, Buerger Katharina, Fliessbach Klaus, Freiesleben Silka Dawn, Frommann Ingo, Glanz Wenzel, Heneka Michael T, Janowitz Daniel, Kilimann Ingo, Kleineidam Luca, Lammerding Dominik, Laske Christoph, Munk Matthias H J, Perneczky Robert, Peters Oliver, Priller Josef, Rauchmann Boris-Stephan, Rostamzadeh Ayda, Roy-Kluth Nina, Schild Ann-Katrin, Schneider Anja, Schneider Luisa-Sophie, Spottke Annika, Spruth Eike Jakob, Teipel Stefan, Wagner Michael, Wiltfang Jens, Wolfsgruber Steffen, Duezel Emrah, Jessen Frank, DELCODE Study Group
Аннотация
OBJECTIVE: To identify participant clusters based on stage 2 features and assess their association with amyloid positivity in cognitively unimpaired individuals.
METHODS: We included baseline data of N = 338 cognitively unimpaired participants from the DELCODE cohort with data on cerebrospinal fluid biomarkers for AD. Classification into the AD continuum (i.e., amyloid positivity, A+) was based on Aβ42/40 status. Neuropsychological test data were used to assess subtle objective cognitive dysfunction (OBJ), the subjective cognitive decline interview (SCD-I) was used to detect SCD, and the Neuropsychiatric Inventory Questionnaire (NPI-Q) was used to assess NPS. A two-step cluster analysis was carried out and differences in AD biomarkers between clusters were analyzed.
RESULTS: We identified three distinct participant clusters based on presented symptoms. The highest rate of A+ participants (47.6%) was found in a cluster characterized by both OBJ and SCD. A cluster of participants that presented with SCD and NPS (A+:26.6%) and a cluster of participants with overall few symptoms (A+:19.7%) showed amyloid positivity in a range that was not higher than the expected A+ rate for the age group. Across the full sample, participants with a combination of SCD and OBJ in the memory domain showed a lower Aβ42/ptau181 ratio compared to those with neither SCD nor OBJ.
CONCLUSIONS: The cluster characterized by participants with OBJ and concomitant SCD was enriched for amyloid pathology.